Corcept Therapeutics Says Patients In The Open-Label Phase Exhibited Clinically Meaningful And Statistically Significant Improvements In Hypertension, Hyperglycemia And Other Key Secondary And Exploratory Endpoints
Corcept Therapeutics Says Patients In The Open-Label Phase Exhibited Clinically Meaningful And Statistically Significant Improvements In Hypertension, Hyperglycemia And Other Key Secondary And Exploratory Endpoints
Corcept Therapeutics表示，处于开放标签阶段的患者在高血压、高血糖和其他关键次要和探索性终点方面表现出具有临床意义和统计学意义的改善
Corcept Therapeutics Says Patients In The Open-Label Phase Exhibited Clinically Meaningful And Statistically Significant Improvements In Hypertension, Hyperglycemia And Other Key Secondary And Exploratory Endpoints
Corcept Therapeutics表示，处于开放标签阶段的患者在高血压、高血糖和其他关键次要和探索性终点方面表现出具有临床意义和统计学意义的改善
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。